ReviewJournal of neural transmission (Vienna, Austria : 1996)2023
Tools and criteria to select patients with advanced Parkinson's disease for device-aided therapies: a narrative review.
Review in Journal of neural transmission (Vienna, Austria : 1996), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed.
- Continuous infusion therapy after deep brain stimulation in Parkinson's disease: indications, outcomes, and patient selection.Journal of neural transmission (Vienna, Austria : 1996) · 2026Review
- Psychiatric consultation outcomes in deep brain stimulation candidacy: clinical and psychosocial correlates from a retrospective cohort.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2026Article
- Continuous Subcutaneous Foslevodopa/Foscarbidopa in Advanced Parkinson's Disease.Movement disorders clinical practice · 2026Article
- Large language models as a screening tool for the qualification of patients with Parkinson's disease for device-aided therapies.Journal of neural transmission (Vienna, Austria : 1996) · 2026Article
- Beyond "Advanced": proposing Fluctuation-Dominant Parkinson's disease as a functional alternative to enable timely device-aided therapy.Journal of neural transmission (Vienna, Austria : 1996) · 2026Review
- Tracking Motor Progression and Device-Aided Therapy Eligibility in Parkinson's Disease.Annals of clinical and translational neurology · 2026Article
- Effects of levodopa-entacapone-carbidopa intrajejunal infusion on non-motor symptoms of advanced Parkinson's disease-interim analysis of the ELEGANCE study.Journal of neural transmission (Vienna, Austria : 1996) · 2026Article
- Motor and non-motor fluctuations in Parkinson's disease: the knowns and unknowns of current therapeutic approaches.Journal of neural transmission (Vienna, Austria : 1996) · 2026Review
- Profile of People With Parkinson's Disease Treated With a Device-Aided Therapy in Spain. A Comparative Multicenter Observational Study.Movement disorders clinical practice · 2026Observational
- Impact of device-aided therapies on quality of life in patients with Parkinson's disease. A comparative multicenter observational study.Journal of neural transmission (Vienna, Austria : 1996) · 2025Article
- Health-Related Quality of Life in Relation to the 5-2-1 Criteria in Parkinson's Disease in Sweden.Movement disorders clinical practice · 2025Article
- Assessing Eligibility for Apomorphine Therapy in Parkinson's Disease: The Telemonitoring Potential.Movement disorders clinical practice · 2025Article
- The role of intraoperative monitoring in target selection in deep brain stimulation: A single centre study.Clinical parkinsonism & related disorders · 2025Article
- Device-aided therapies (DATs) in Parkinson's disease (PD). The DATs-PD GETM Spanish Registry Protocol Study.PloS one · 2025Article
- Perspectives on digital health and advanced treatment referral in Parkinson's care among Danish neurologists: a mixed methods study.Frontiers in neurology · 2025Article
- Use of the MNCD Classification to Monitor Clinical Stage and Response to Levodopa-Entacapone-Carbidopa Intestinal Gel Infusion in Advanced Parkinson's Disease.Brain sciences · 2024Article
- Grasping the big picture: impact analysis of screening tools for timely referral for device-aided therapies.Journal of neural transmission (Vienna, Austria : 1996) · 2024Review
- What was first and what is next in selecting device-aided therapy in Parkinson's disease? Balancing evidence and experience.Journal of neural transmission (Vienna, Austria : 1996) · 2024Review
- Utilization of MANAGE-PD Tool in a Real-World Setting in Germany: A Cross-Sectional Study.Brain sciences · 2024Article
- Levodopa-Entacapone-Carbidopa Intestinal Gel in the Treatment of Advanced Parkinson's Disease: A Single Center Real-World Experience.Pharmaceutics · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This article provides an overview of the various screening and selection tools which have been developed over the past 25 years to identify patients with Parkinson's disease (PD) possibly eligible for device-aided therapies (DATs). For the available screening tools, we describe the target therapies (subtypes of DAT), development methods, validation data, and their use in clinical practice. In addition, the historical background and potential utility of these screening tools are discussed. The challenges in developing and validating these tools are also addressed, taking into account the differences in population, the local health care organization, and resource availability.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.